Novo Nordisk Wagers $2.9 Billion on Pipeline Deals as Denecimig Review Slips and CagriSema Trails Lilly

Novo Nordisk inked Hengrui and Nanexa licensing deals, saw CagriSema trail Zepbound, and absorbed an FDA review extension for Denecimig.

Novo Nordisk has moved aggressively on the deal-making front, locking up two external partnerships in the space of four days while simultaneously absorbing a fresh regulatory setback and a competitive miss in the obesity arena. The Danish drugmaker's shares closed at 33.13 EUR, down 25% year-to-date and roughly 40% below their 52-week high of 54.86 EUR.

Two Licensing Deals in Four Days

On September 29, Novo Nordisk signed an agreement with Jiangsu Hengrui Pharmaceuticals covering the drug candidate HRS-1596. The pact grants the Copenhagen-based group exclusive rights to develop, manufacture, and commercialize the compound outside mainland China, Hong Kong, Macau, and Taiwan. Novo Nordisk will pay $300 million upfront, with milestone payments that could reach $2.6 billion in total, plus future royalties.

Four days earlier, on September 25, the company had already struck a worldwide exclusive licensing and collaboration deal with Nanexa centered on the latter's PharmaShell platform. That agreement spans up to five development programs for peptide-based medicines and carries a potential payout of up to EUR 1.165 billion — comprising as much as EUR 615 million for upfront, development, and approval milestones, and up to EUR 550 million tied to sales targets.

The twin moves signal a deliberate push to broaden the clinical pipeline through outside partnerships rather than purely in-house research.

Oral Semaglutide Switch Data Land

Fresh clinical evidence arrived on September 30 at the annual meeting of the European Association for the Study of Diabetes, where investigators presented results from the OCTANE trial. The study followed 194 participants who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide. Over three months, subjects shed an average of 4.1% of their body weight.

The findings carry weight because dosing convenience is emerging as a key competitive lever, and the ability to pair novel delivery platforms such as PharmaShell with new molecules like HRS-1596 could determine whether Novo Nordisk sustains its growth trajectory over the coming decade. Reuters, however, noted that the OCTANE results were based in part on self-reported data, meaning no causal relationship can be drawn from them.

CagriSema Falls Short of Zepbound

In the obesity segment — the company's dominant revenue engine — the combination therapy CagriSema delivered somewhat less weight loss than Eli Lilly's rival product Zepbound. CEO Mike Doustdar nonetheless pointed to the 23% weight reduction achieved in the trial. An FDA decision on CagriSema is anticipated by the end of 2026, with results from the follow-up REDEFINE 11 study, involving 600 participants, expected in the first half of 2027.

FDA Extends Denecimig Review

Regulatory friction is adding to the pressure. The FDA has extended its review of Denecimig, a candidate for preventing bleeding episodes in hemophilia A, citing outstanding remediation work at a manufacturing facility. The application was submitted in September 2025, and no new decision date has been set.

Novo Nordisk maintains that no efficacy or safety deficiencies were identified, that its 2026 financial guidance remains unchanged, and that it still targets a US market launch in the first half of 2027. In Europe, the Committee for Medicinal Products for Human Use has already issued a positive opinion, though the European Commission's formal decision is still pending.

To sharpen its commercial positioning in rare diseases, the company is also surveying patient priorities. A study conducted in Germany is capturing the preferences of adult hemophilia patients regarding protection, safety, and the mode of administration of hypothetical preventive therapies — data intended to help refine the product profile against established standard treatments.

Buybacks Offset the Drag

Management is leaning on capital returns to shore up the shareholder base. Under a program authorized for up to DKK 15 billion, Novo Nordisk had repurchased roughly 36.6 million of its own B shares for a total of DKK 10.25 billion by early October. The tranche runs through February 2027 and is designed to return surplus cash to investors.

Despite the recent headwinds, the group's market capitalization stands at EUR 146.96 billion, keeping it a heavyweight in the sector.

What Has to Go Right

The path to a durable recovery hinges on a handful of conditions. As long as the 2026 financial guidance holds firm despite the Denecimig delay, the fundamental framework stays intact — and the Hengrui and Nanexa licenses provide a viable basis for medium- and long-term upside. If the Denecimig timetable slips further or additional manufacturing defects surface, selling pressure is likely to persist, and the risk of delays beyond the targeted first half of 2027 would keep market participants on edge.

The first half of 2027 looms as the next major catalyst, when Novo Nordisk aims to launch Denecimig in the United States. Until then, the partner programs will need to show early translational progress to give investors a reason to re-rate the stock.